In 141 patients with advanced pancreatic NETs, 12-month first-line PFS did not differ significantly between everolimus first and STZ/5-FU first (71.4% vs 61.8%; OR 0.65); STZ/5-FU gave a higher first-line response rate (30.3% vs 11.6%).
RCTn = 141
Capdevila et al. Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial